BioMed Research International

BioMed Research International / 2018 / Article
Special Issue

Natural Compounds against Cancer, Inflammation, and Oxidative Stress

View this Special Issue

Research Article | Open Access

Volume 2018 |Article ID 3120972 |

Hoang Le Tuan Anh, Phuong Thao Tran, Do Thi Thao, Duong Thu Trang, Nguyen Hai Dang, Pham Van Cuong, Phan Van Kiem, Chau Van Minh, Jeong-Hyung Lee, "Degalactotigonin, a Steroidal Glycoside from Solanum nigrum, Induces Apoptosis and Cell Cycle Arrest via Inhibiting the EGFR Signaling Pathways in Pancreatic Cancer Cells", BioMed Research International, vol. 2018, Article ID 3120972, 9 pages, 2018.

Degalactotigonin, a Steroidal Glycoside from Solanum nigrum, Induces Apoptosis and Cell Cycle Arrest via Inhibiting the EGFR Signaling Pathways in Pancreatic Cancer Cells

Guest Editor: Cinzia Forni
Received11 Sep 2018
Accepted04 Nov 2018
Published16 Dec 2018


Degalactotigonin (1) and three other steroidal compounds solasodine (2), O-acetyl solasodine (3), and soladulcoside A (4) were isolated from the methanolic extract of Solanum nigrum, and their chemical structures were elucidated by spectroscopic analyses. The isolated compounds were evaluated for cytotoxic activity against human pancreatic cancer cell lines (PANC1 and MIA-PaCa2) and lung cancer cell lines (A549, NCI-H1975, and NCI-H1299). Only degalactotigonin (1) showed potent cytotoxicity against these cancer cell lines. Compound 1 induced apoptosis in PANC1 and A549 cells. Further study on its mechanism of action in PANC1 cells demonstrated that 1 significantly inhibited EGF-induced proliferation and migration in a concentration-dependent manner. Treatment of PANC1 cells with degalactotigonin induced cell cycle arrest at G0/G1 phase. Compound 1 induced downregulation of cyclin D1 and upregulation of p21 in a time- and concentration-dependent manner and inhibited EGF-induced phosphorylation of EGFR, as well as activation of EGFR downstream signaling molecules such as Akt and ERK.

1. Introduction

Pancreatic cancer is the 12th most common cancer worldwide and is the most seventh deathly related-cancer. Surgical resection and chemotherapeutics are the traditional treatment of pancreatic cancer. The recent success of chemotherapy treatments is based on the inhibition of tumor-associated specific pathways and commonly referred to as targeted agents [1]. For instances, some inhibitors of the epidermal growth factor receptors (EGFR) were approved by FDA for the treatment of several cancer types including pancreatic cancer [24]. However, these commonly used techniques are frequently challenged in view of metastasis and other pathological changes. Therefore, the search for new antipancreatic cancer agents is important to reduce the mortality rate.

Overexpression of growth factors and their receptors, inactivation of tumor suppressor gene, or activation of oncogene is the stimulators for the growth of an aggressive cancer [5]. EGFR and its family members are the main components of a complex signaling cascade that regulates proliferation, growth, migration, differentiation, and survival of cancer cells [6]. Thirteen known ligands that can activate the EGFR family include epidermal growth factor (EGF), amphiregulin (AR), betacellulin (BTC), transforming growth factor alpha (TGF-), epiregulin (EPR), epigen (EPG), neuregulins 1–6 (NRG), and heparin-binding EGF-like growth factor (HB-EGF) [7]. The activation of EGFR leads to the phosphorylation of specific tyrosine residues on the intracellular cytoplasmic tail, which results in the activation of corresponding signaling cascades critically in cell proliferation, survival, migration, and angiogenesis. EGFR then undergoes endocytosis to recycle or direct to lysosomes for degradation, resulting in the downregulation of EGFR signaling [8]. Receptor tyrosine kinases including EGFR, PDGFRα (platelet-derived growth factor receptor-α), and VEGFR (vascular endothelial growth factor receptor) have been detected to be activated in pancreatic cancer. Noteworthily, overexpression of EGFR is found up to 90% in pancreatic cancer cells [9]. Though EGFR expression has been supported to growth and metastatic stages of cancer [10], its effects on survival is still a debate [11, 12]. Overall, EGFR is an emerging candidate for further research in pancreatic cancer therapy.

Solanum nigrum L. (Solanaceae) has been used in traditional medicine for the treatment of edema, diuretic, inflammation, mastitis, and hepatic cancer [13]. Recent studies showed that the aqueous extract of S. nigrum leaves induced autophagy and enhanced cytotoxicity of some chemotherapy drugs in HT-29 human colorectal carcinoma cells [14]. The antitumor properties of extracts from various parts of this plant have been reported [1518]. Furthermore, the anti-inflammatory, antinociceptive, antineoplastic, antiulcerogenic, and antiviral activities of extracts and compounds of S. nigrum were demonstrated [1925]. Studies on the chemical properties of this plants revealed that alkaloids, glycoproteins, flavonoids, and steroidal glycosides are the major contents, among which, the cytotoxicity of alkaloids and glycoproteins of S. nigrum were reported [2630]. It is assumed that these contents mostly contribute to the antitumor properties of this plant [3036]. The previous studies indicated that steroidal glycosides from S. nigrum are also the major constituents with potential anticancer activities [3739]. Degalactotigonin, a steroidal glycoside of this plant, showed potent cytotoxicity against multiple cell lines [40]. This compound is considered to be the most cytotoxic steroidal glycoside isolated from S. nigrum to date. A recent report demonstrated that this compound suppressed the growth and metastasis of osteosarcoma [41]. In this study, we presented the isolation of some steroidal glycoside from the leaves of S. nigrum and evaluated their cytotoxic properties on human lung and pancreatic cell lines. We also investigated for the first time the mechanism of action of cytotoxic degalactotigonin in human pancreatic cancer cell line PANC1.

2. Materials and Methods

2.1. Plant Materials

The plant S. nigrum was collected in August 2015 at Thaibinh province, Vietnam, and was identified by Dr. Do Thanh Tuan, Thaibinh University of Medicine and Pharmacy. The voucher specimen (TB16.2015) was deposited at the Herbarium of Mientrung Institute for Scientific Research (VAST) and Thaibinh University of Medicine and Pharmacy.

2.2. Isolation of Compounds 1-4 from Solanum nigrum

The whole plant of S. nigrum was air dried, ground to powder, and extracted with methanol at 50°C with the aid of ultrasonic (3 times x 1 h each). The organic layer was filtered and removed under vacuum to obtain the crude extract of methanol. This crude extract was suspended in hot distilled water (1.5 L) and successively partitioned with dichloromethane and ethyl acetate (3 times x 1.5 L each) to yield corresponding extracts, dichloromethane (SND, 30 g), ethyl acetate (SNE, 32 g), and water-soluble layer (SNW). The SNW layer was passed through a Diaion HP-20 column, washed with distilled water, and eluted with increasing volume of methanol in water (25%, 50%, 75%, and 100% of methanol) to obtain four subfractions, SNW1–SNW4. The subfraction SNW3 (2,5 g) was chromatographed on a silica gel column and eluted with solvent system of dichloromethane/methanol/water (2.0/1.0/0.1, v/v/v) to obtain four smaller fractions, SNW1A-SNW1D. The fraction SNW1B (0.6 g) was chromatographed on a silica gel column and eluted with dichloromethane/methanol (3.0/1.0, v/v) and then was further purified on an RP-18 reversed phase column and eluted with acetone/water (1.0/2.0, v/v) to yields 2 (11.0 mg) and 3 (14.0 mg). The fraction SNW1D (1.2 g) was separated into 2 fractions, SNW2A - SNW2B, on a silica gel column eluting with solvent system dichloromethane/methanol/water (4.0/1.0/0.1, v/v/v). The fraction SNW2A (0.2 g) was further purified on a silica gel column and eluted with dichloromethane/methanol/water (2.0/1.0/0.1, v/v/v) to yield 4 (7.0 mg). Compound 1 (50.0 mg) was obtained from fraction SNW2B (0.4 g) on a silica gel column eluting with dichloromethane/acetone/water (1.5/1.0/0.1, v/v/v).

2.3. Antibodies and Reagents

EGF was purchased from Invitrogen (Carlsbad, CA, USA). Antibodies including anti-EGFR, anticyclin D1, and anti-p21 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-phospho-EGFR, anti-Akt, anti-phospho Akt (Ser473), anti-ERK, and anti-phospho-ERK antibodies were from Cell Signaling Technology (Danvers, MA, USA).

2.4. Cell Culture

All cell lines used in this study were obtained from the American Type Culture Collection (Manassas, VA, USA). A549, NCI-H1975, and NCI-H1299 cells were maintained in RPMI 1640 medium. PANC1 and MIA-PaCa2 cells were maintained in DMEM. All media were supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA) and streptomycin-penicillin (Invitrogen, Carlsbad, CA, USA). Cultures were maintained in a CO2 incubator humidified atmosphere 5% CO2 at 37°C.

2.5. Cell Viability Assay

The cytotoxic activity of 1-4 was determined by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]-based colorimetric assay [42]. MTT was purchased from Sigma, MO, USA. In brief, 2 × 105 cells/mL were seeded into 96-well plate and incubated for overnight. The compounds were treated to each well with various concentrations (0, 1, 3, 10, and 30 µM). After incubation for 48 h, the MTT solution (0.5 mg/mL) was added to each well and further incubated for 3 h. Cell viability was calculated as a percentage compared to the vehicle-only treated control sample and performed in triplicate. The IC50 values were calculated using nonlinear regression analysis (percentage survival versus concentration).

2.6. Western Blot Analysis

Cells were harvested and lysed in a lysis buffer [150 mM NaCl, 50 mM Tris-HCl, pH 7.4, 1 mM EDTA, and 1% NP-40, 5 mM sodium orthovanadate, and protease inhibitors cocktail (BD Biosciences)] and then centrifuged for 10 min at 4°C and 15,000 rpm. An equal amount of protein was separated onto SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) and transferred to a Hybond-P membrane (Amersham Biosciences, Buckinghamshire, UK). Membranes were blocked in 5% nonfat skim milk for 1 h at room temperature, probed with the appropriate primary antibodies (1:1,000 dilution), washed, and then incubated with the corresponding secondary antibody (1:2,000 dilution). The signal was detected using the ECL (enhanced chemiluminescence) system (Intron, Seongnam, Korea).

2.7. Annexin V and PI Double Staining Assay

Annexin V and PI (propidium iodide) staining for apoptosis detection was performed using an Annexin V–FLOUS kit according to the manufacturer’s instructions (BD Biosciences, CA, USA). Briefly, cells were treated with various concentrations of 1 and incubated for 24 h. The cells were then collected by trypsinization, washed 2 times with cold PBS, suspended in 100 µL of a binding buffer (dilute from 10X binding buffer), and stained with 5 µL PI (stock solution 50 µg/mL) and 5 µL FITC-labeled Annexin V in the dark for 15 min at room temperature. The cells were analyzed by FACS Calibur (Becton Dickinson, CA, USA). The percentages of Annexin V+/PI- (apoptosis cells), Annexin V /PI- (living cells), and Annexin V+ /PI+ (necrotic cells) staining were determined after marking for the positive and negative population.

2.8. Cell Cycle Analysis

Cells were seeded into 60 mm culture dishes and serum-starved in DMEM containing 0.5% FBS for 24 h. The cells were treated with indicated concentrations of 1 for 30 min and then stimulated by EGF (100 ng/mL) for 24 h. The cells were harvested by trypsinization, washed two times with cold PBS, and then centrifuged. The collected cells were fixed in 70% ethanol (v/v) for at least 2 hours at 4°C, washed once with PBS, and then suspended in cold propidium iodide (PI) solution (50 µg/mL) containing RNase A (0.1 µg/mL) in PBS (pH 7.4) in the dark for 15 min at room temperature. Flow cytometry analyses were performed using FACS Calibur (Becton Dickinson, CA, USA). The data were analyzed using the Cell Quest software (Becton Dickinson, CA, USA).

2.9. Cell Migration Assay

Cell migration assays were performed by following the Boyden chamber method using polycarbonate membranes with an 8 μm pore size. In brief, 105 cells were seeded onto the upper chamber in 200 μL of DMEM containing 0.5% FBS, and then the upper chamber was put onto the 24-well plate with 800 μL of the same media with or without EGF (100 ng/ml). The various concentrations of 1 (0, 0.1, 0.3, and 1 µM) were treated in the upper chamber. After 12 h incubation, the migrated cells on the lower surface of the filter were fixed in methanol and then stained with H&E (hematoxylin and eosin). The cotton swabs were used to remove the cells which did not migrate through the pore. The migrated cells were counted in at least five randomly selected microscopic fields (×100) per filter.

2.10. Statistical Analysis

Data was expressed as the mean ± standard deviations (SD). Statistical significance was assessed by the two-tailed unpaired Student’s t-test and P values less than 0.05 was considered statistically significant.

3. Results and Discussion

3.1. Isolation and Identification of Compounds 1-4

Compounds 1-4 were isolated from the methanolic extracts of S. nigrum by using various chromatographic techniques. Their structures were elucidated by using spectroscopic data (Supplementary Data (available here)) and by comparison with the reported data [39, 43, 44]. The compounds were determined as degalactotigonin (1), solasodine (2), O-acetyl solasodine (3), and soladulcoside A (4) (Figure 1).

3.2. Degalactotigonin Induces Apoptosis in PANC1 and A549 Cells

Cytotoxic activities of the isolated compounds on five human cancer cell lines (lung cancer cell lines: A549, NCI-H1975 and NCI-H1299; pancreatic cancer lines: PANC1 and MIA-PaCa2) were evaluated by an MTT method. As a result, compound 1 showed to be the most active compound against all tested cell lines (Table 1). The results were in accordance with those of previous reports in which degalactotigonin showed the cytotoxicity against various cancer cell lines including PC-12 (human lung carcinoma), HCT-116 (human colon carcinoma), NCI-H460 (human lung carcinoma), HepG2 (human liver carcinoma), MCF-7 (human breast carcinoma), and SF-268 (human glioma) [39, 40]. Further studies demonstrated that this compound induced apoptosis in MCF-7 cells and suppressed the growth and metastasis of human osteosarcoma through modulation of GSK-3β inactivation–mediated repression of the Hedgehog/Gli1 pathway [41, 45].

CompoundsIC50 (M)

14.9 ± 1.05.5 ± 0.66.3 ± 0.82.9 ± 0.26.4 ± 0.4
3>30>3027.9 ± 3.0>30>30
428.4 ± 3.1>30>30>30>30
Camptothecin1.5 ± 0.90.16 ± 0.10.24 ± 0.14.7 ± 0.53.3 ± 0.2

IC50 values were calculated in a triplicate experiment.
used as positive control.

We determined apoptosis-inducing activity of 1 in PANC1 and A549 cells by Annexin V/PI double staining assays. Treatment with 1 increased the ration of apoptotic cells (Annexin V positive) in a concentration-dependent manner in these cells and PANC1 cells were more sensitive to apoptosis induced by 1 than A549 cells (Figures 2(a) and 2(b)). Since PANC1 cells were the most sensitive to 1 (Table 1) and expressed the highest level of EGFR compared to other tested cell lines (Figure 2(c)), we further investigated on the mechanism of action of 1 in PANC1 cells.

3.3. Degalactotigonin Inhibits EGF-Induced Cell Cycle Progression of PANC1 Cells

EGF acts as a regulator of cell proliferation, growth and migration by binding to its receptor EGFR [46]. We determined whether 1 inhibits EGF-induced cell cycle progression of PANC1 cells. Serum starvation of PANC1 cells for 24 h resulted in approximately 55.% synchronization of the cell cycle at the G0/G1 phase. The percentage of S phase cells increased from 5.8% to 11.2% after treatment with EGF (100 ng/mL) for 24 h. In contrast, treatment with 1 at 0.3 μM significantly induced cell cycle arrest at G0/G1 phase by increasing the percentage of cells up to 52.2% and reducing the S phase to 9.0% (Figure 3(a)), suggesting that 1 could inhibit EGF-induced cell cycle progression via inhibiting EGFR signaling pathway. However, treatment with higher concentration of 1 (1 μM and 3 μM) induced cell death due to its cytotoxicity in serum-starved condition.

Cyclin D1 and p21 are two important regulators in the G1/S phase progression and downstream target genes of the EGFR signaling pathway. p21 (also known as Waf1/Cip1), a well-known cyclin-dependent kinase inhibitor, is involved in regulation of the cell cycle and acts as a mediator of cell survival as well as inhibiting DNA synthesis [47, 48]. Overexpression of p21 can potentially inhibit cyclin D1/CDK4 complex and suppress the catalytic activity of this complex, leading to cell cycle arrest at G1 phase [49]. Western blot analyses revealed that stimulation of PANC1 cells with EGF increased the expression levels of cyclin D1 and p21 in a time-dependent manner (Figure 3(b)). Treatment of PANC1 cells with 1 inhibited EGF-induced expression of cyclin D1 (Figure 3(c)), suggesting that 1 could inhibit EGFR signaling pathway. However, treatment with 1 further increased the expression level of p21 in PANC1 cells (Figure 3(c)). In osteosarcoma cancer cells, 1 increases p21 mRNA and protein expression through undefined mechanisms and induces cell cycle arrest [41]. Thus, it is likely that 1 induces p21 expression via EGFR-independent signaling pathway and the induction of p21 by 1 may significantly contribute to the inhibition of EGF-induced cell cycle progression.

3.4. Degalactotigonin Suppresses EGF-Induced Activation of EGFR in PANC1 Cells

After EGF binding to EGFR in the cell membrane, EGFR is autophosphorylated, endocytosis, and recycled or directed to lysosomes for degradation [50]. We determined whether 1 regulates EGFR activation in response to EGF stimulation. Serum-starved PANC1 cells were treated with 1 at different concentrations for 30 min followed by EGF stimulation for 5 min. Treatment with 1 significantly reduced the level of EGFR phosphorylation (Y1068) (Figure 4(a)), suggesting that 1 may inhibit EGFR activation. Next, we examined whether 1 inhibits the activation of EGFR downstream signaling molecules such as Akt and ERK (extracellular signal-regulated kinase) [33]. The PI3K (phosphatidylinositol 3-kinase)/Akt pathway is activated in many cancers, and inhibition of the PI3K/Akt pathway induces cell apoptosis [51]. The activation of Ras/Raf/ERK by growth factor triggers the synthesis of D-type cyclins which bind with Cdk4 or Cdk6 to regulate cell cycle progression [52]. Treatment of PANC1 cells with 1 inhibited EGF-induced Akt (Ser473) and ERK (Thr202/Tyr204) phosphorylation (Figures 4(b) and 4(c)) in a concentration-dependent manner. Taken together, these results suggested that 1 may inhibit EGF-mediated activation of EGFR and subsequent EGFR downstream signaling molecules such as Akt and ERK.

3.5. Degalactotigonin Attenuates EGF-Induced Migration of PANC1 Cells

In the tumor progression, acquisition of the invasive and metastatic capability is important characteristics, which correlate with poor clinical prognosis and become the barrier to successful treatment [53]. EGF is a well-known growth factor that promotes cancer cell migration and motility [5456]. To further investigate the inhibitory effect of 1 on EGF-induced signaling, we determined whether 1 inhibits EGF-induced migration of PANC1 cells by transwell migration assay. The results showed that 1 markedly decreased the migration of PANC1 cells induced by EGF in a dose-dependent manner (Figure 5), suggesting that 1 effectively suppressed EGF-mediated migration of PANC1 cells via inhibiting EGFR signaling pathway.

Pancreatic cancer is one of the most common deathly cancers in the Western world [57]. Overexpression of EGFR has been detected up to 90% in this cancer [9]. Gefitinib and erlotinib were the first EGFR tyrosine kinase inhibitors to be developed. Both of them target blocking EGFR signaling downstream pathways as competitive inhibitors of ATP for the tyrosine kinase domain [58]. Degalactotigonin (1), a saponin isolated from Solanum nigrum, has chemopreventive effects on various cancer types [45]. However, the anticancer effects of 1 and its mode of action mechanism in pancreatic cancer cells have not been investigated yet. In this study, we demonstrated that 1 induced apoptosis in PANC cells. Notably, compound 1 reduced EGF-induced phosphorylation of EGFR and its downstream signaling molecules such as Akt and ERK and suppressed the EGF-induced proliferation and migration of PANC1 cells in a dose-dependent manner.

Taken together, this study showed that 1 not only suppressed proliferation and migration of PANC1 cells, but also induced cell cycles arrest at G0/G1 phase and apoptosis via inhibiting EGF-mediated EGFR activation. These results might clarify a novel biological mechanism for 1 in antitumor therapy targeted on EGFR-overexpressing pancreatic cancer.

Data Availability

The data used to support the findings of this study are included within the supplementary information file.

Conflicts of Interest

The authors declare no competing financial interest.

Authors’ Contributions

Hoang Le Tuan Anh and Phuong Thao Tran make equal contributions to this work.


This research is funded by the Vietnam National Foundation for Science and Technology Development (NAFOSTED) under Grant no. 106.02-2017.20 and Kangwon National University.

Supplementary Materials

The spectroscopic data of the isolated compounds used to support the findings of this study are included within the supplementary information file. (Supplementary Materials)


  1. S. A. Danovi, H. H. Wong, and N. R. Lemoine, “Targeted therapies for pancreatic cancer,” British Medical Bulletin, vol. 87, no. 1, pp. 97–130, 2008. View at: Publisher Site | Google Scholar
  2. C. J. Bruns, M. T. Harbison, D. W. Davis et al., “Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms,” Clinical Cancer Research, vol. 6, no. 5, pp. 1936–1948, 2000. View at: Google Scholar
  3. C. Bangard, A. Gossmann, A. Papyan, S. Tawadros, M. Hellmich, and C. J. Bruns, “Magnetic resonance imaging in an orthotopic rat model: Blockade of epidermal growth factor receptor with EMD72000 inhibits human pancreatic carcinoma growth,” International Journal of Cancer, vol. 114, no. 1, pp. 131–138, 2005. View at: Publisher Site | Google Scholar
  4. M. H. Kulke, L. S. Blaszkowsky, D. P. Ryan et al., “Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer,” Journal of Clinical Oncology, vol. 25, no. 30, pp. 4787–4792, 2007. View at: Publisher Site | Google Scholar
  5. S. J. Zunino, Y. Zhang, N. P. Seeram, and D. H. Storms, “Berry fruit extracts inhibit growth and induce apoptosis of high-risk acute lymphoblastic leukemia cells in vitro,” Journal of Functional Foods, vol. 2, no. 3, pp. 187–195, 2010. View at: Publisher Site | Google Scholar
  6. D. S. Salomon, R. Brandt, F. Ciardiello, and N. Normanno, “Epidermal growth factor-related peptides and their receptors in human malignancies,” Critical Review in Oncology/Hematology, vol. 19, no. 3, pp. 183–232, 1995. View at: Publisher Site | Google Scholar
  7. S. R. Hubbard and W. T. Miller, “Receptor tyrosine kinases: mechanisms of activation and signaling,” Current Opinion in Cell Biology, vol. 19, no. 2, pp. 117–123, 2007. View at: Publisher Site | Google Scholar
  8. P. Seshacharyulu, M. P. Ponnusamy, D. Haridas, M. Jain, A. K. Ganti, and S. K. Batra, “Targeting the EGFR signaling pathway in cancer therapy,” Expert Opinion on Therapeutic Targets, vol. 16, no. 1, pp. 15–31, 2012. View at: Publisher Site | Google Scholar
  9. A. Citri and Y. Yarden, “EGF-ERBB signalling: towards the systems level,” Nature Reviews Molecular Cell Biology, vol. 7, no. 7, pp. 505–516, 2006. View at: Publisher Site | Google Scholar
  10. K. Tobita, H. Kijima, S. Dowaki et al., “Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis,” International Journal of Molecular Medicine, vol. 11, no. 3, pp. 305–309, 2003. View at: Publisher Site | Google Scholar
  11. K. Uegaki, Y. Nio, Y. Inoue et al., “Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer,” Anticancer Reseach, vol. 17, no. 5 B, pp. 3841–3847, 1997. View at: Google Scholar
  12. Y. Zhang, S. Banerjee, Z.-W. Wang, D. J. Marciniak, A. P. N. Majumdar, and F. H. Sarkar, “Epidermal growth factor receptor-related protein inhibits cell growth and induces apoptosis of BxPC3 pancreatic cancer cells,” Cancer Research, vol. 65, no. 9, pp. 3877–3882, 2005. View at: Publisher Site | Google Scholar
  13. R. Jain, A. Sharma, S. Gupta, I. P. Sarethy, and R. Gabrani, “Solanum nigrum: current perspectives on therapeutic properties,” Alternative Medicine Review, vol. 16, no. 1, pp. 78–85, 2011. View at: Google Scholar
  14. C. J. Tai, C. K. Wang, C. J. Tai et al., “Aqueous extract of solanum nigrum leaves induces autophagy and enhances cytotoxicity of cisplatin, doxorubicin, docetaxel, and 5-fluorouracil in human colorectal carcinoma cells,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 514719, 12 pages, 2013. View at: Publisher Site | Google Scholar
  15. H. C. Wang, P. J. Chung, C. H. Wu, K. P. Lan, M. Y. Yang, and C. J. Wang, “Solanum nigrum L. polyphenolic extract inhibits hepatocarcinoma cell growth by inducing G2/M phase arrest and apoptosis,” Journal of the Science of Food and Agriculture, vol. 91, no. 1, pp. 178–185, 2011. View at: Publisher Site | Google Scholar
  16. H. M. Lin, H. C. Tseng, C. J. Wang et al., “Induction of autophagy and apoptosis by the extract of Solanum nigrum Linn in HepG2 cells,” Journal of Agricultural and Food Chemistry, vol. 55, no. 9, pp. 3620–3628, 2007. View at: Publisher Site | Google Scholar
  17. J. Li, Q. Li, T. Feng et al., “Antitumor activity of crude polysaccharides isolated from Solanum nigrum Linne on U14 cervical carcinoma bearing mice,” Phytotherapy Research, vol. 21, no. 9, pp. 832–840, 2007. View at: Publisher Site | Google Scholar
  18. J. Li, Q.-W. Li, D.-W. Gao, Z.-S. Han, and K. Li, “Antitumor effects of total alkaloids isolated from Solanum nigrum in vitro and in vivo,” Die Pharmazie, vol. 63, no. 7, pp. 534–538, 2008. View at: Publisher Site | Google Scholar
  19. Z. A. Zakaria, H. K. Gopalan, and H. Zainal, “Antinociceptive, anti-inflammatory and antipyretic effects of Solanum nigrum chloroform extract in animal models,” Yakugaku Zasshi, vol. 126, no. 11, pp. 1171–1178, 2006. View at: Publisher Site | Google Scholar
  20. H. Kang, H.-D. Jeong, and H.-Y. Choi, “The chloroform fraction of solanum nigrum suppresses nitric oxide and tumor necrosis factor-α in LPS-stimulated mouse peritoneal macrophages through inhibition of p38, JNK and ERK1/2,” American Journal of Chinese Medicine, vol. 39, no. 6, pp. 1261–1273, 2011. View at: Publisher Site | Google Scholar
  21. F.-P. Liu, X. Ma, M.-M. Li et al., “Hepatoprotective effects of Solanum nigrum against ethanol-induced injury in primary hepatocytes and mice with analysis of glutathione S-transferase A1,” Journal of the Chinese Medical Association, vol. 79, no. 2, pp. 65–71, 2016. View at: Publisher Site | Google Scholar
  22. L. Xiang, Y. Wang, X. Yi, and X. He, “Anti-inflammatory steroidal glycosides from the berries of Solanum nigrum L. (European black nightshade),” Phytochemistry, vol. 148, pp. 87–96, 2018. View at: Publisher Site | Google Scholar
  23. L. Zhao, L. Wang, S. Di et al., “Steroidal alkaloid solanine A from Solanum nigrum Linn. exhibits anti-inflammatory activity in lipopolysaccharide/interferon γ-activated murine macrophages and animal models of inflammation,” Biomedicine & Pharmacotherapy, vol. 105, pp. 606–615, 2018. View at: Publisher Site | Google Scholar
  24. K. Hu, H. Kobayashi, A. Dong, Y. Jing, S. Iwasaki, and X. Yao, “Antineoplastic agents III: steroidal glycosides from solanum nigrum,” Planta Medica, vol. 65, no. 1, pp. 35–38, 1999. View at: Publisher Site | Google Scholar
  25. T. Javed, U. A. Ashfaq, S. Riaz, S. Rehman, and S. Riazuddin, “In-vitro antiviral activity of Solanum nigrum against Hepatitis C Virus,” Virology Journal, vol. 8, article 26, 2011. View at: Publisher Site | Google Scholar
  26. X. Ding, F. Zhu, Y. Yang, and M. Li, “Purification, antitumor activity in vitro of steroidal glycoalkaloids from black nightshade (Solanum nigrum L.),” Food Chemistry, vol. 141, no. 2, pp. 1181–1186, 2013. View at: Publisher Site | Google Scholar
  27. L. An, J. T. Tang, X. M. Liu, and N. N. Gao, “Review about mechanisms of anti-cancer of Solanum nigrum,” Journal of Chinese Materia Medica, vol. 31, no. 15, pp. 1225-1226, 1260. View at: Google Scholar
  28. F. Kalalinia and I. Karimi-Sani, “Anticancer properties of solamargine: a systematic review,” Phytotherapy Research, vol. 31, no. 6, pp. 858–870, 2017. View at: Publisher Site | Google Scholar
  29. B. Pan, W. Zhong, Z. Deng et al., “Inhibition of prostate cancer growth by solanine requires the suppression of cell cycle proteins and the activation of ROS/P38 signaling pathway,” Cancer Medicine, vol. 5, no. 11, pp. 3214–3222, 2016. View at: Publisher Site | Google Scholar
  30. Y. Yi, X. Jia, J. Wang, J. Chen, H. Wang, and Y. Li, “Solanine induced apoptosis and increased chemosensitivity to Adriamycin in T-cell acute lymphoblastic leukemia cells,” Oncology Letters, vol. 15, no. 5, pp. 7383–7388, 2018. View at: Google Scholar
  31. K.-S. Heo and K.-T. Lim, “Glycoprotein isolated from Solarium nigrum L. modulates the apoptotic-related signals in 12-O-tetradecanoylphorbol 13-acetate-stimulated MCF-7 cells,” Journal of Medicinal Food, vol. 8, no. 1, pp. 69–77, 2005. View at: Publisher Site | Google Scholar
  32. S.-J. Lee and K.-T. Lim, “150 kDa glycoprotein isolated from Solanum nigrum Linne stimulates caspase-3 activation and reduces inducible nitric oxide production in HCT-116 cells,” Toxicology in Vitro, vol. 20, no. 7, pp. 1088–1097, 2006. View at: Publisher Site | Google Scholar
  33. S.-J. Lee, P.-S. Oh, J.-H. Ko, K. Lim, and K.-T. Lim, “A 150-kDa glycoprotein isolated from Solanum nigrum L. has cytotoxic and apoptotic effects by inhibiting the effects of protein kinase C alpha, nuclear factor-kappa B and inducible nitric oxide in HCT-116 cells,” Cancer Chemotherapy and Pharmacology, vol. 54, no. 6, pp. 562–572, 2004. View at: Publisher Site | Google Scholar
  34. K.-T. Lim, “Glycoprotein isolated from Solanum nigrum L. kills HT-29 cells through apoptosis,” Journal of Medicinal Food, vol. 8, no. 2, pp. 215–226, 2005. View at: Publisher Site | Google Scholar
  35. X. Ding, F.-S. Zhu, M. Li, and S.-G. Gao, “Induction of apoptosis in human hepatoma SMMC-7721 cells by solamargine from Solanum nigrum L.,” Journal of Ethnopharmacology, vol. 139, no. 2, pp. 599–604, 2012. View at: Publisher Site | Google Scholar
  36. I. K. Sani, S. H. Marashi, and F. Kalalinia, “Solamargine inhibits migration and invasion of human hepatocellular carcinoma cells through down-regulation of matrix metalloproteinases 2 and 9 expression and activity,” Toxicology in Vitro, vol. 29, no. 5, pp. 893–900, 2015. View at: Publisher Site | Google Scholar
  37. T. Ikeda, H. Tsumagari, and T. Nohara, “Steroidal oligoglycosides from Solanum nigrum,” Chemical & Pharmaceutical Bulletin, vol. 48, no. 7, pp. 1062–1064, 2000. View at: Publisher Site | Google Scholar
  38. M. Ohno, K. Murakami, M. El-Aasr et al., “New spirostanol glycosides from Solanum nigrum and S. jasminoides,” Journal of Natural Medicines, vol. 66, no. 4, pp. 658–663, 2012. View at: Publisher Site | Google Scholar
  39. X. Zhou, X. He, G. Wang et al., “Steroidal saponins from Solanum nigrum,” Journal of Natural Products, vol. 69, no. 8, pp. 1158–1163, 2006. View at: Publisher Site | Google Scholar
  40. T. Ikeda, H. Tsumagari, T. Honbu, and T. Nohara, “Cytotoxic activity of steroidal glycosides from solanum plants,” Biological & Pharmaceutical Bulletin, vol. 26, no. 8, pp. 1198–1201, 2003. View at: Publisher Site | Google Scholar
  41. Z. Zhao, Q. Jia, M. Wu et al., “Degalactotigonin, a Natural Compound from,” Clinical Cancer Research, vol. 24, no. 1, pp. 130–144, 2018. View at: Publisher Site | Google Scholar
  42. T. Mosmann, “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays,” Journal of Immunological Methods, vol. 65, no. 1-2, pp. 55–63, 1983. View at: Publisher Site | Google Scholar
  43. X. Zha, H. Sun, J. Hao, and Y. Zhang, “Efficient synthesis of solasodine, O-acetylsolasodine, and soladulcidine as anticancer steroidal alkaloids,” Chemistry & Biodiversity, vol. 4, no. 1, pp. 25–31, 2007. View at: Publisher Site | Google Scholar
  44. T. Yamashita, T. Matsumoto, S. Yahara, N. Yoshida, and T. Nohara, “Structures of Two New Steroidal Glycosides, Soladulcosides a and B From Solanum dulcamara,” Chemical and Pharmaceutical Bulletin, vol. 39, no. 6, pp. 1626–1628, 1991. View at: Publisher Site | Google Scholar
  45. D. Chakraborty, C. K. Jain, A. Maity et al., “Chenopodium album metabolites act as dual topoisomerase inhibitors and induce apoptosis in the MCF7 cell line,” MedChemComm, vol. 7, no. 5, pp. 837–844, 2016. View at: Publisher Site | Google Scholar
  46. N. Normanno, A. de Luca, C. Bianco et al., “Epidermal growth factor receptor (EGFR) signaling in cancer,” Gene, vol. 366, no. 1, pp. 2–16, 2006. View at: Publisher Site | Google Scholar
  47. Y. Li, D. Dowbenko, and L. A. Lasky, “AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival,” The Journal of Biological Chemistry, vol. 277, no. 13, pp. 11352–11361, 2002. View at: Publisher Site | Google Scholar
  48. A. Karimian, Y. Ahmadi, and B. Yousefi, “Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage,” DNA Repair, vol. 42, pp. 63–71, 2016. View at: Publisher Site | Google Scholar
  49. M. Fu, C. Wang, Z. Li, T. Sakamaki, and R. G. Pestell, “Minireview: Cyclin D1: Normal and abnormal functions,” Endocrinology, vol. 145, no. 12, pp. 5439–5447, 2004. View at: Publisher Site | Google Scholar
  50. A. Tomas, C. E. Futter, and E. R. Eden, “EGF receptor trafficking: consequences for signaling and cancer,” Trends in Cell Biology, vol. 24, no. 1, pp. 26–34, 2014. View at: Publisher Site | Google Scholar
  51. L. Rössig, A. S. Jadidi, C. Urbich, C. Badorff, A. M. Zeiher, and S. Dimmeler, “Akt-dependent phosphorylation of p21Cip1 regulates PCNA binding and proliferation of endothelial cells,” Molecular and Cellular Biology, vol. 21, no. 16, pp. 5644–5657, 2001. View at: Publisher Site | Google Scholar
  52. K. M. Regula, M. J. Rzeszutek, D. Baetz, C. Seneviratne, and L. A. Kirshenbaum, “Therapeutic opportunities for cell cycle re-entry and cardiac regeneration,” Cardiovascular Research, vol. 64, no. 3, pp. 395–401, 2004. View at: Publisher Site | Google Scholar
  53. Z. Lu, G. Jiang, P. Blume-Jensen, and T. Hunter, “Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase,” Molecular and Cellular Biology, vol. 21, no. 12, pp. 4016–4031, 2001. View at: Publisher Site | Google Scholar
  54. J. T. Price, H. M. Wilson, and N. E. Haites, “Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704,” European Journal of Cancer Part A: General Topics, vol. 32, no. 11, pp. 1977–1982, 1996. View at: Publisher Site | Google Scholar
  55. E. M. Rosen and I. D. Goldberg, “Protein factors which regulate cell motility,” In Vitro Cellular & Developmental Biology, vol. 25, no. 12, pp. 1079–1087, 1989. View at: Publisher Site | Google Scholar
  56. T. Shibata, T. Kawano, H. Nagayasu et al., “Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth,” Tumor Biology, vol. 17, no. 3, pp. 168–175, 1996. View at: Publisher Site | Google Scholar
  57. D. Hariharan, A. Saied, and H. M. Kocher, “Analysis of mortality rates for pancreatic cancer across the world,” HPB, vol. 10, no. 1, pp. 58–62, 2008. View at: Publisher Site | Google Scholar
  58. B. A. Chan and B. G. Hughes, “Targeted therapy for non-small cell lung cancer: current standards and the promise of the future,” Translational Lung Cancer Research, vol. 4, no. 1, pp. 36–54, 2015. View at: Google Scholar

Copyright © 2018 Hoang Le Tuan Anh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.